Phase 2Completed
Randomized Study of Obicetrapib in Combination With Ezetimibe (OCEAN)
A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe in Participants With Mild Dyslipidemia
- Sponsor
- NewAmsterdam Pharma (Industry)
- Enrollment
- 112 enrolled
- Conditions
- Dyslipidemias; High Cholesterol; Hypercholesterolemia
- Interventions
- Obicetrapib 5mg; Ezetimibe 10mg; Placebo
- Ages
- adults, older adults
- Registry
- NCT04770389
Full record on ClinicalTrials.gov
From the registry
This study will be a placebo-controlled, double-blind, randomized, phase 2 study in participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of obicetrapib and ezetimibe combination therapy.
Primary outcomes
- Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]
- Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]
- LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [Friedewald]
- Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 57: Obicetrapib in Combination With Ezetimibe Compared to Placebo [PUC]
History
Results first posted
Last registry update
Study completion
Primary completion
Registered
Started